Full Press Release Details
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference
HUNTSVILLE, AL, April 7, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE American SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the Jones Healthcare and Technology Innovation Conference in Las Vegas, NV on April 9, 2025, at 3 00 p.m. PDT.
A live webcast of the presentation will be accessible to registered attendees at https wsw.com webcast jones2 ser 1739658. An archived replay will be available on-demand for 90 days following the event.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina's POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https serinatherapeutics.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management's current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina's POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities whether regulatory authorities will be satisfied with the design of and results from our clinical studies whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful decisions by regulatory authorities impacting labeling, manufacturing processes, safety and or other matters that could affect the availability or commercial potential of any drug or vaccine candidates and competitive developments. These risks as well as other risks are more fully discussed in Serina's Annual Report on Form 10-K, and Serina's other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact
sriley serinatherapeutics.com